A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HRE2-positive primary breast cancer

Project: Research

StatusActive
Effective start/end date28/02/1927/02/24